BLTE Chief Medical Officer Peter Sells $1.5M of Stock

Scholl Hendrik Peter, the Chief Medical Officer of Belite Bio, Inc, sold 10,000 shares of the company on June 18, 2026. The shares were sold at an average price of $145.24, totaling approximately $1.45 million. This transaction was not conducted under a pre-planned trading program.

Insider Buying and Selling at Belite Bio, Inc

In addition to Scholl's recent sale, Nathan Mata, Belite Bio's Chief Scientific Officer, also sold shares earlier in May. His transactions were part of a pre-planned trading program, with sales ranging from $153.21 to $155.64 per share.

Other Institutional Activity in Belite Bio, Inc

Several institutional investors have been adjusting their positions in Belite Bio. DARWIN GLOBAL MANAGEMENT, LTD. increased its stake by 29,708 shares, bringing its total to over 3.05 million shares valued at about $456.1 million. PARADIGM BIOCAPITAL ADVISORS LP initiated a new position with 1,114,784 shares worth approximately $177.7 million. UBS GROUP AG notably boosted its holdings by 639,607 shares, a 496.8% increase, to a total of 768,359 shares valued at around $122.5 million. Meanwhile, RTW INVESTMENTS, LP maintained its position with no change in shares, holding approximately 715,332 shares worth $114 million.

Belite Bio, Inc Stock Down 14.5%

Shares of NasdaqCM:BLTE traded near $146.12 on Monday. Belite Bio, Inc has a market cap of about $5.86 billion and a forward P/E ratio of 154.74. The stock's beta is -1.243, indicating it moves inversely to the market. Belite Bio's 52-week range spans from $56.10 to $200.00, with a 50-day moving average of $151.91 and a 200-day moving average of $138.36. The company holds a strong current ratio of 33.71, reflecting its robust liquidity position.

Analysts Set New Price Targets

On May 26, 2026, Mizuho maintained its 'buy' rating on Belite Bio with a price target of $215. HC Wainwright & Co. reiterated a 'buy' rating with a $200 price target on May 21, 2026. Analysts generally view Belite Bio positively, with a consensus recommendation of 'strong buy' and an average price target of $210.50 based on eight analyst opinions.

About Belite Bio, Inc

Belite Bio, Inc is a biotechnology company based in San Diego, California. It focuses on developing novel therapeutics for unmet medical needs. The company's lead product, Tinlarebant, is in phase 3 trials for treating retinal diseases. Belite is also working on LBS-009, targeting liver diseases and type 2 diabetes. Dr. Yu-Hsin Lin leads the company as CEO, guiding its efforts in the healthcare sector.

Bottom Line

Belite Bio, Inc's recent insider sales and institutional activities are notable for investors tracking the company's performance. While insider transactions can be informative, they don't necessarily predict future stock movements. The data from these events is backward-looking, reflecting past actions and may not indicate current or future positions.